European Commission grants marketing authorization for Gilead’s Zydelig® (Idelalisib) for the treatment of chronic lymphocytic leukemia and follicular lymphoma
22 September 2014 | By Gilead Sciences
Gilead Sciences, Inc. announced that the European Commission has granted marketing authorization for Zydelig® (idelalisib), 150 mg tablets, a first-in-class oral treatment for two incurable blood cancers - chronic lymphocytic leukemia and follicular lymphoma...